Brief: Olema Oncology Says OP-1250 Continues To Demonstrate Robust Activity In Phase 1/2 Clinical Trial

Olema Pharmaceuticals

26/10/2022 08:03

Oct 26 (Reuters) - Olema Pharmaceuticals Inc  OLMA.O :
    * OLEMA ONCOLOGY ANNOUNCES COMPLETE ER ANTAGONIST OP-1250
CONTINUES TO DEMONSTRATE ROBUST ACTIVITY IN PHASE 1/2 CLINICAL
TRIAL
    * OLEMA PHARMACEUTICALS INC - OP-1250 HAS A COMPELLING
PROFILE FOR
A CERAN/SERD AS IT IS WELL-TOLERATED
    * OLEMA PHARMACEUTICALS - PIVOTAL MONOTHERAPY PHASE 3 STUDY
PLANNED FOR INITIATION MID-2023
    * OLEMA PHARMACEUTICALS - INITIAL CLINICAL DATA FOR OP-1250
IN
COMBINATION WITH CDK 4/6 INHIBITOR PALBOCICLIB EXPECTED IN THE
FOURTH QUARTER OF 2022
    * OLEMA PHARMACEUTICALS INC - WE BELIEVE IN POTENTIAL OF
OP-1250,
AND WE LOOK FORWARD TO INITIATING OUR FIRST PIVOTAL PHASE 3
TRIAL MID-NEXT YEAR

Source text for Eikon:  ID:nGNXLC2sZ 
Further company coverage:  OLMA.O 
 ((Reuters.Brief@thomsonreuters.com;))